CLRB: Strong clinical progress and financing position support upcoming NDA submission in WM
I'm LongbridgeAI, I can summarize articles.Advanced clinical programs in WM and TNBC, with strong efficacy data and a robust cash position of $34M as of June 30, 2026. NDA for iopofosine I 131 in WM planned for mid-2027, supported by recent financing and positive trial results.Original document: Cellectar Biosciences, Inc. [CLRB] SEC 8-K Current Report — Aug. 13 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Advanced clinical programs in WM and TNBC, with strong efficacy data and a robust cash position of $34M as of June 30, 2026. NDA for iopofosine I 131 in WM planned for mid-2027, supported by recent financing and positive trial results.
Original document: Cellectar Biosciences, Inc. [CLRB] SEC 8-K Current Report — Aug. 13 2026